IDEAYA Biosciences, Inc. (IDYA): Price and Financial Metrics


IDEAYA Biosciences, Inc. (IDYA): $25.94

-0.16 (-0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IDYA POWR Grades


  • Value is the dimension where IDYA ranks best; there it ranks ahead of 79.84% of US stocks.
  • IDYA's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • IDYA ranks lowest in Sentiment; there it ranks in the 6th percentile.

IDYA Stock Summary

  • IDYA's went public 2.32 years ago, making it older than merely 4.97% of listed US stocks we're tracking.
  • IDYA's price/sales ratio is 28.29; that's higher than the P/S ratio of 92.27% of US stocks.
  • As for revenue growth, note that IDYA's revenue has grown 81.91% over the past 12 months; that beats the revenue growth of 92.19% of US companies in our set.
  • Stocks that are quantitatively similar to IDYA, based on their financial statements, market capitalization, and price volatility, are JNCE, SRPT, WVE, ASMB, and ABUS.
  • Visit IDYA's SEC page to see the company's official filings. To visit the company's web site, go to www.ideayabio.com.

IDYA Valuation Summary

  • In comparison to the median Healthcare stock, IDYA's price/earnings ratio is 182.47% lower, now standing at -30.1.
  • IDYA's price/earnings ratio has moved down 24.4 over the prior 28 months.
  • IDYA's EV/EBIT ratio has moved down 22.2 over the prior 28 months.

Below are key valuation metrics over time for IDYA.

Stock Date P/S P/B P/E EV/EBIT
IDYA 2021-08-31 25.4 3.8 -30.1 -27.2
IDYA 2021-08-30 24.7 3.7 -29.3 -26.5
IDYA 2021-08-27 24.8 3.7 -29.3 -26.5
IDYA 2021-08-26 24.3 3.6 -28.7 -25.9
IDYA 2021-08-25 25.0 3.7 -29.6 -26.8
IDYA 2021-08-24 25.6 3.8 -30.3 -27.5

IDYA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IDYA has a Quality Grade of C, ranking ahead of 34.75% of graded US stocks.
  • IDYA's asset turnover comes in at 0.113 -- ranking 255th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows IDYA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.113 1 -0.163
2021-03-31 0.096 1 -0.224
2020-12-31 0.088 1 -0.295
2020-09-30 0.051 1 -0.455
2020-06-30 0.000 NA -0.699
2020-03-31 0.000 NA -0.647

IDYA Price Target

For more insight on analysts targets of IDYA, see our IDYA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.78 Average Broker Recommendation 1.22 (Strong Buy)

IDYA Stock Price Chart Interactive Chart >

Price chart for IDYA

IDYA Price/Volume Stats

Current price $25.94 52-week high $28.00
Prev. close $26.10 52-week low $11.20
Day low $25.25 Volume 156,334
Day high $26.15 Avg. volume 228,109
50-day MA $22.99 Dividend yield N/A
200-day MA $20.09 Market Cap 996.17M

IDEAYA Biosciences, Inc. (IDYA) Company Bio


IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


IDYA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDYA Latest Social Stream


Loading social stream, please wait...

View Full IDYA Social Stream

Latest IDYA News From Around the Web

Below are the latest news stories about IDEAYA Biosciences Inc that investors may wish to consider to help them evaluate IDYA as an investment opportunity.

SVP And Chief Scientific Officer Of Ideaya Biosciences Trades $394.04 Thousand In Company Stock

Michael P Dillon, SVP And Chief Scientific Officer at Ideaya Biosciences (NASDAQ:IDYA), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 8, Michael P Dillon bought 11,500 Ideaya Biosciences shares at prices ranging from $4.31 to $11.08 per share, for a total of $78,764. They then sold their shares on succeeding transactions in the open market at pric

Yahoo | September 10, 2021

IDEAYA Biosciences to Participate in Investor Conferences in September 2021

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in September 2021.

Yahoo | August 30, 2021

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have made a decent return of 99% over the past year

If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

Yahoo | August 16, 2021

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -371.43% and -12.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 10, 2021

IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2021.

Yahoo | August 10, 2021

Read More 'IDYA' Stories Here

IDYA Price Returns

1-mo 10.29%
3-mo 14.32%
6-mo 14.88%
1-year 98.17%
3-year N/A
5-year N/A
YTD 85.29%
2020 86.67%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7943 seconds.